benefit of two of the newer drugs for osteoporosis

November 1998

There's good news about the benefit of two of the newer drugs for osteoporosis...Evista (raloxifene) and Fosamax (alendronate).

Evista has now been shown to prevent FRACTURES...initially it was shown just to increase bone density.

Evista cuts the risk of spinal fractures in half...in postmenopausal women who take it for two years. There's no info yet on whether Evista reduces hip fractures.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote